Drug profile · INN
aducanumab-avwa
ADUHELM
aducanumab-avwa (ADUHELM) is a amyloid-beta a4 protein binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — aducanumab-avwa
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
aducanumab-avwa (ADUHELM) is a amyloid-beta a4 protein binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Amyloid-beta A4 protein binding agent
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is aducanumab-avwa?
aducanumab-avwa (ADUHELM) is a amyloid-beta a4 protein binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for aducanumab-avwa?
ADUHELM is a marketed brand name for aducanumab-avwa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of aducanumab-avwa?
aducanumab-avwa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.